{
  "ticker": "NC6",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959236",
  "id": "02959236",
  "pages": 9,
  "price_sensitive": false,
  "date": "20250617",
  "time": "1400",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250617/pdf/06ktscrxbhwszl.pdf",
  "summary": "### Summary of ASX Announcement (Nanollose Limited - Appendix 3G)  \n\n- **Security Issuance Details**:  \n  - **6,000,000 Performance Rights** issued to CEO (part of remuneration), expiring **14 July 2028**.  \n  - **15,000,000 Options** (Tranche A) with:  \n    - Exercise price: **AUD 0.07**  \n    - Expiry: **30 May 2028**  \n  - **15,000,000 Options** (Tranche B) with:  \n    - Exercise price: **AUD 0.10**  \n    - Expiry: **30 May 2028**  \n  - Issued under Listing Rule 7.1 (15% placement capacity), no shareholder approval required.  \n\n- **Total Unquoted Securities**:  \n  - **6M Performance Rights** + **30M New Options** (Tranche A & B).  \n  - Additional unquoted options outstanding (see Part 4.2 for full list).  \n\n- **Impact**: Equity dilution potential if options exercised; no immediate cash inflow.  \n\n*No material trading or capital raising timetable details provided.*",
  "usage": {
    "prompt_tokens": 2960,
    "completion_tokens": 254,
    "total_tokens": 3214,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T05:29:46.173939"
}